GABA(B) Receptor Agonists Reduce Operant Ethanol Self-administration and Enhance Ethanol Sedation in C57BL/6J Mice

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2004 Feb 27

PMID 14985930

Citations 35

Authors

Joyce Besheer

Veronique Lepoutre

Clyde W Hodge

Affiliations

Soon will be listed here.

Abstract

Rationale: A growing number of studies suggest that gamma-aminobutyric acid type-B (GABA(B)) receptor agonists reduce alcohol use and craving.

Objectives: This study was designed to further clarify behavioral mechanism(s) by which GABA(B) agonists may decrease alcohol reinforcement.

Methods: Male C57BL/6 J mice were trained to lever press on a concurrent schedule of ethanol (10% v/v) and water reinforcement during 16-h overnight sessions. Effects of the GABA(B) agonist baclofen (0-17 mg/kg, IP) or SKF 97541 (0-1 mg/kg, IP) were examined on parameters of self-administration. Subsequently, potential motor inhibition and interaction with ethanol-induced sedation by GABA(B) agonists was examined in ethanol naive and self-administering mice.

Results: Baclofen (10 mg/kg) and SKF 97541 (0.3 mg/kg) reduced ethanol-reinforced responding. In a locomotor activity test, these doses of the GABA(B) agonists inhibited locomotion in the ethanol-experienced mice and in a group of ethanol-inexperienced mice; locomotor suppression was greater in the ethanol-inexperienced mice. These doses of the GABA(B) agonists also potentiated the sedative effects of ethanol (4 g/kg) and converted a nonsedative dose of ethanol (2 g/kg) into a fully sedative dose. GABA(B) agonist enhancement of the sedative effects of ethanol was less pronounced in ethanol self-administering mice, suggesting cross-tolerance at the low dose of ethanol.

Conclusions: GABA(B) agonists decrease the reinforcing effects of ethanol at doses that inhibit locomotor activity and potentiate the sedative hypnotic effects of ethanol. These nonspecific effects of GABA(B) agonists were reduced in alcohol experienced mice, suggesting cross-tolerance to the inhibitory properties of GABA(B) positive modulation. These data question the safety of prescribing GABA(B) agonists to alcoholics since these drugs may potentiate ethanol's sedative/hypnotic effects during relapse.

Citing Articles

Smooth operator(s): dialing up and down neurotransmitter responses by G-protein regulators.

Philibert C, Garcia-Marcos M Trends Cell Biol. 2024; .

PMID: 39054106 PMC: 11757802. DOI: 10.1016/j.tcb.2024.07.002.

GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential.

Dharavath R, Pina-Leblanc C, Tang V, Sloan M, Nikolova Y, Pangarov P Front Neural Circuits. 2023; 17:1218737.

PMID: 37929054 PMC: 10623140. DOI: 10.3389/fncir.2023.1218737.

Systemic administration of racemic baclofen reduces both acquisition and maintenance of alcohol consumption in male and female mice.

Bauer M, Hernandez M, Kasten C, Boehm 2nd S Alcohol. 2022; 103:25-35.

PMID: 35870740 PMC: 9835998. DOI: 10.1016/j.alcohol.2022.06.003.

Reducing effect of the novel positive allosteric modulator of the GABA receptor, COR659, on binge-like alcohol drinking in male mice and rats.

Lorrai I, Shankula C, Marquez Gaytan J, Kawamura T, Maccioni P, Mugnaini C Psychopharmacology (Berl). 2021; 239(1):201-213.

PMID: 34812900 DOI: 10.1007/s00213-021-06022-3.

Recent Advances in the Potential of Positive Allosteric Modulators of the GABAB Receptor to Treat Alcohol Use Disorder.

Augier E Alcohol Alcohol. 2021; 56(2):139-148.

PMID: 33561865 PMC: 7906877. DOI: 10.1093/alcalc/agab003.

References

De Luca C, Massotti M . Phaclofen antagonizes the antinociceptive but not the sedative effects of (-)-baclofen. Prog Neuropsychopharmacol Biol Psychiatry. 1990; 14(4):597-607. DOI: 10.1016/0278-5846(90)90011-5. View

Munzar P, Kutkat S, Miller C, Goldberg S . Failure of baclofen to modulate discriminative-stimulus effects of cocaine or methamphetamine in rats. Eur J Pharmacol. 2000; 408(2):169-74. DOI: 10.1016/s0014-2999(00)00772-x. View

Agmo A, Giordano M . The locomotor-reducing effects of GABAergic drugs do not depend on the GABAA receptor. Psychopharmacology (Berl). 1985; 87(1):51-4. DOI: 10.1007/BF00431777. View

McBride W, Noronha A . Central nervous system mechanisms in alcohol relapse. Alcohol Clin Exp Res. 2002; 26(2):280-6. View

Allan A, Burnett D, Harris R . Ethanol-induced changes in chloride flux are mediated by both GABA(A) and GABA(B) receptors. Alcohol Clin Exp Res. 1991; 15(2):233-7. DOI: 10.1111/j.1530-0277.1991.tb01862.x. View

Colombo G, Serra S, Brunetti G, Atzori G, Pani M, Vacca G . The GABA(B) receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats. Alcohol Alcohol. 2002; 37(5):499-503. DOI: 10.1093/alcalc/37.5.499. View

Anstrom K, Cromwell H, Markowski T, Woodward D . Effect of baclofen on alcohol and sucrose self-administration in rats. Alcohol Clin Exp Res. 2003; 27(6):900-8. DOI: 10.1097/01.ALC.0000071744.78580.78. View

Allan A, Harris R . A new alcohol antagonist: phaclofen. Life Sci. 1989; 45(19):1771-9. DOI: 10.1016/0024-3205(89)90516-x. View

Levy R, Proudfit H . The analgesic action of baclofen [beta-(4-chlorophenyl)-gamma-aminobutyric acid]. J Pharmacol Exp Ther. 1977; 202(2):437-45. View

10.

Shelton K, Balster R . Ethanol drug discrimination in rats: substitution with GABA agonists and NMDA antagonists. Behav Pharmacol. 1994; 5(4 And 5):441-451. View

11.

Zarrindast M . Food intake suppressant effect of baclofen in rats. Gen Pharmacol. 1989; 20(5):701-3. DOI: 10.1016/0306-3623(89)90110-9. View

12.

Colombo G, Agabio R, Carai M, Lobina C, Pani M, Reali R . Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence. Alcohol Clin Exp Res. 2000; 24(1):58-66. View

13.

Martz A, Deitrich R, Harris R . Behavioral evidence for the involvement of gamma-aminobutyric acid in the actions of ethanol. Eur J Pharmacol. 1983; 89(1-2):53-62. DOI: 10.1016/0014-2999(83)90607-6. View

14.

Faigle J, KEBERLE H . The chemistry and kinetics of Lioresal. Postgrad Med J. 1972; 48:Suppl 5:9-13. View

15.

Cousins M, Roberts D, de Wit H . GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend. 2002; 65(3):209-20. DOI: 10.1016/s0376-8716(01)00163-6. View

16.

Gianutsos G, Moore K . Tolerance to the effects of baclofen and gamma-butyrolactone on locomotor activity and dopaminergic neurons in the mouse. J Pharmacol Exp Ther. 1978; 207(3):859-69. View

17.

Frye G, Taylor L, Trzeciakowski J, GRIFFITH W . Effects of acute and chronic ethanol treatment on pre- and postsynaptic responses to baclofen in rat hippocampus. Brain Res. 1991; 560(1-2):84-91. DOI: 10.1016/0006-8993(91)91218-p. View

18.

SAMSON H . Initiation of ethanol reinforcement using a sucrose-substitution procedure in food- and water-sated rats. Alcohol Clin Exp Res. 1986; 10(4):436-42. DOI: 10.1111/j.1530-0277.1986.tb05120.x. View

19.

Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L . Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002; 37(5):504-8. DOI: 10.1093/alcalc/37.5.504. View

20.

Cott J, Carlsson A, Engel J, Lindqvist M . Suppression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn Schmiedebergs Arch Pharmacol. 1976; 295(3):203-9. DOI: 10.1007/BF00505087. View